IO Reddit Mentions | ChartExchange

**I think this one is a GREAT opportunity for a multiples return!** I have 70,000 shares.
* 8/13/2026: **SP** \~ $0.26 to $0.28 / \~ **MC** $10M
* **Underpriced/mispriced in a big way!**
* **Emerging Growth Research: 12-mth Price Target - $10.00**
* It's a holding company, currently with 3 subsidiaries/product lines.
* **Vaximm's VMX01 drug:** encouraging Phase 1 trial data in pancreatic cancer
* P2 trial completed in recurrent gioblastoma (GBM) **in collaboration with Merck, Darmstadt, Germany and Pfizer**.
* Submitting GBM trial results for peer review.
* FDA and European Commission **Orphan designation**.
* **Darnatein:** platform that uses AI to generate "hybrid" endogenous proteins.
* **DRT 101:** super-agonist for joint cartilage regeneration.
* **Woori IO:** non-invasive glucose monitoring device.
* Seeking Big Tech partnerships in the wearables market.
**Current Status:**
* Facing a delisting letter on or about the **Aug 31 deadline** (2nd 180-day period ends).
* CEO said the Board decided not to reverse split.
* Instead, they put in place a CVR shareholder loyalty program for shareholders of record today, 8/14. Check this out: [OSR Health](https://osr-health.com/loyaltyprogram). It gives a great idea of where the CEO believes their share price should/could be and the time frames.
* **The CEO is an excellent** **communicator to shareholders** (refer to the 3 or 4 very recent shareholder letters, one was this week). Shareholders want companies with CEO's that operate this way to succeed.
* **Signed an $815M milestone-based licensing agreement for VMX01, with BCM Europe!**
* **Includes a $15M put that can be exercised in Oct 2026 at $10 per share as part of that contract (negligible dilution).**
* The CEO sent the below Aug 11 shareholder letter that states the have had two inquiries for out-licensing of their products: **one is preliminary term sheet negotiation phase and the other is early stage.**
* [OSR Health CEO Reaffirms Confidence and Highlights Subsidiary Business Development : OSR Health](https://osr-health.com/news/?q=YToxOntzOjEyOiJrZXl3b3JkX3R5cGUiO3M6MzoiYWxsIjt9&bmode=view&idx=173027274&t=board)
* **The CEO stated that he is also trying to move up the October $15M put date.**
**IMO, here's how things should unfold going forward:**
* On or about **Aug 18**, the "practical deadline," OSRH will receive a NASDAQ delisting determination letter.
* OSRH will file a request for hearing. They have 7 calendar days to do so.
* **By Aug 25**, NASDAQ will receive the request.
* Per AI, upon NASDAQ receiving the request, it automatically STAYS the delisting.
* **By** **Aug 28** (within 3 days) NASDAQ will reply with an acknowledgement letter granting the request.
* **By Sep 9 to Sep 29** (within 10 to 20 days after the acknowledgement letter) OSRH will receive notification of a hearing date, which is typically set **30 to 45 days from the date of the hearing request**.
* Between Sep 24 and Oct 9, the hearing should take place.
NASDAQ delisting hearing panels love to see a plan with real catalysts. Per AI, the typical length of extension they grant is 30 to 45 days for the company to become compliant.
IMO, OSRH should be valued far above $1 right now, solely based on its VMX01 P2 results. **It's a hidden gem with great potential!**
There are many biotechs in P1/P2 (oncology and cardiology) that have MCs between $50M and even up to $150M and even some higher.
* **In my opinion, OSRH should be trading at a MC of between $50M to $100M RIGHT NOW -- a 5x to 10x opportunity if priced competitively.** A couple of examples with a quick search:
* Cardiff Oncology (**CRDF**) - P2 completed - **$76M MC** \- PLK1 inhibitor
* Immutep (**IMMP**) - P2 completed - **$58M** **MC** \- LAG-3 immunotherapy
I found another biotech hidden gem that has unbelievable potential (P3 completed) and is greatly underpriced. I hope to make a post about it soon.